Adalimumab


Adalimumab, sold under the brand name Humira and others, is a disease-modifying antirheumatic drug and monoclonal antibody used to treat rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa, and uveitis. It is administered by subcutaneous injection. It works by inactivating tumor necrosis factor.
Common side effects include upper respiratory tract infections, pain at the site of injection, rash, and headache. Other side effects may include serious infections, cancer, anaphylaxis, reactivation of hepatitis B, new onset or exacerbation of demyelinating diseases, heart failure, liver failure, and aplastic anemia. Use during pregnancy is not recommended, but some sources show use during breastfeeding may be safe.
Adalimumab was approved for medical use in the United States in 2002. It is on the World Health Organization's List of Essential Medicines. It is available as a biosimilar medication. In 2023, it was the 244th most commonly prescribed medication in the United States, with more than 3million prescriptions.

Medical uses

In the US and the EU, adalimumab is indicated for the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult and pediatric Crohn's disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa, and uveitis. In the EU it is also indicated for chronic aggressive progressive pulmonary and bone sarcoidosis.

Rheumatoid arthritis

Adalimumab has been shown to reduce the signs and symptoms of moderate to severe rheumatoid arthritis in adults. It may be used alone or in combination with disease-modifying antirheumatic drugs. It has also been shown to have efficacy in moderate to severe polyarticular juvenile idiopathic arthritis in children four years and older, and is indicated for the treatment of that condition. In rheumatoid arthritis, it is indicated for use alone, or with methotrexate or similar medicines, in the United States since 2002. It has a similar effectiveness as methotrexate and, in combination, nearly doubles the response rate of methotrexate alone.

Juvenile idiopathic arthritis

Adalimumab has been shown to reduce the signs and symptoms of moderate to severe polyarticular juvenile idiopathic arthritis in children aged four years and older.

Ankylosing spondylitis

Adalimumab has been shown to reduce the signs and symptoms of, and is approved for treatment for, ankylosing spondylitis in adults.

Crohn's disease

Adalimumab has been shown to reduce the signs and symptoms of moderate to severe Crohn's disease. It has been approved for that use in the UK since 2009.

Ulcerative colitis

Adalimumab may be effective and well tolerated in ulcerative colitis. It was approved by the US Food and Drug Administration for treatment of moderate to severe cases in adults.

Plaque psoriasis

Adalimumab has been shown to treat moderate to severe chronic plaque psoriasis in adults who have the condition in many areas of their body and who may benefit from taking injections or pills or phototherapy. Adalimumab has been shown to be effective therapy when used either continuously or intermittently in patients with moderate to severe psoriasis.

Hidradenitis suppurativa

Adalimumab was approved for hidradenitis suppurativa in 2015.

Non-infectious uveitis

Adalimumab is indicated for the treatment of non-infectious uveitis.

Mechanism of action

Adalimumab is a monoclonal antibody. It works by binding to and inhibiting Tumor necrosis factor and inducing apoptosis in mononuclear cells expressing TNF.

Adverse effects

The US FDA label contains a boxed warning about serious infections and malignancies.
There is strong evidence that adalimumab increases risk of serious infections, such as tuberculosis, and it has also been reported to increase the risk of developing various cancers. However, such an association may reflect an increased risk of developing malignancies inherent in the conditions being treated, and not with adalimumab itself. A systematic review published in 2018, found no increased cancer incidence rate in patients with chronic inflammatory disorders treated with adalimumab and other TNF inhibitors, as compared to those who were not, with a possible exception for non-melanoma skin cancer.
Injection site reactions such as redness and pain are very common, and may occur in up to 80% of cases.

History

Adalimumab was the first fully human monoclonal antibody approved by the US Food and Drug Administration. It is derived from phage display.
Adalimumab was discovered as a result of a collaboration between BASF Bioresearch Corporation and Cambridge Antibody Technology, U.K., itself a collaboration of the government-funded Medical Research Council and three academics, which began in 1993.
Initially named D2E7, it was then further manufactured at BASF Bioresearch Corporation, developed by BASF Knoll, and ultimately manufactured and marketed by Abbott Laboratories after Abbott's acquisition of BASF Pharma. On 1 January 2013, Abbott split into two companies, one retaining the Abbott name and the other named AbbVie. As a result, AbbVie took over development and marketing of Humira. The brand name Humira stands for "human monoclonal antibody in rheumatoid arthritis", and was named by one of Abbott's employees, Richard J. Karwoski, who was also responsible for leading the effort to get Humira approved by the FDA.
It is the third TNF inhibitor, after infliximab and etanercept, to be approved in the United States. It is constructed from a fully human monoclonal antibody, while infliximab is a mouse-human chimeric antibody and etanercept is a TNF receptor-IgG fusion protein.
The drug candidate was discovered initially using CAT's phage display technology and named D2E7. The key components of the drug were found by guiding the selection of human antibodies from phage display repertoires to a single epitope of an antigen TNF. The ultimate clinical candidate, D2E7, was created and manufactured at BASF Bioresearch Corporation and taken through most of the drug development process by BASF Knoll, then further development, manufacturing and marketing by Abbott Laboratories, after Abbott acquired the pharmaceutical arm of BASF Knoll.
Since 2008, adalimumab had been approved by the FDA for the treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, moderate to severe chronic psoriasis and juvenile idiopathic arthritis. Although only approved for ulcerative colitis from late 2012, by the FDA in the disease's management, it had been used for several years in cases that have not responded to conventional treatment at standard dosing for Crohn's disease.
Adalimumab, sold under the brand name Humira, was approved for use in the United States in 2002.
Adalimumab, sold under the brand names Humira and Trudexa, was approved for use in the European Union in September 2003.

Research

  • 1999: Preliminary results of early clinical trials with the fully human anti-TNF monoclonal antibody D2E7
  • 2001, June: Results from ARMADA, a double-blind, placebo-controlled clinical trial involving 271 patients with active rheumatoid arthritis despite treatment with methotrexate are announced. Results show that 50% of patients demonstrate a 50% improvement in American College of Rheumatology score.
  • 2002: Broke ground on a new biologics manufacturing facility.
  • 2002: Adalimumab results from five separate trials show that it is effective at reducing signs and symptoms of rheumatoid arthritis and had a rapid onset of action and sustained efficacy. Adalimumab was safe and effective when given alone or in combination with MTX as a subcutaneous injection.
  • 2002: Humira approved by the US Food and Drug Administration for treatment of rheumatoid arthritis.
  • 2003: Launched Humira for rheumatoid arthritis and continued clinical studies for additional indications.
  • 2005: Launched Humira for psoriatic arthritis. Exceeded in annual sales for the first time.
  • 2005: Eisai submits new drug application for adalimumab in Japan.
  • 2006: Submitted Humira for the Crohn's disease indication and launched it for AS. Exceeded in annual sales.
  • 2007: Launched Humira for Crohn's disease in the United States, submitted Humira for global regulatory approval for psoriasis — the fifth Humira disease indication, achieved more than in worldwide Humira sales.
  • 2007: Abbott opens new biotechnology manufacturing facility in Puerto Rico
  • 2008: Launched Humira for plaque psoriasis
  • 2009: Five-Year data demonstrate initial use of humira plus methotrexate may prevent further joint damage in early rheumatoid arthritis patients
  • 2012: Humira could be associated with a significant decrease in vascular inflammation, a major risk factor of cardiovascular disease
  • 2013: Because of the split of Abbott, Humira rights are now owned by AbbVie.
  • 2014: Humira recognized by IMS Health as the "world's best selling drug".
  • 2014: In December 2014, Indian drugmaker Cadila Healthcare declared the launch of the first adalimumab biosimilar at a fifth of its US price. The generic was launched under the brand name Exemptia.
  • 2015: Launched Humira for moderate to severe hidradenitis suppurativa, an orphan indication. No other treatment has been rigorously tested and found to be safe and effective in treating this condition.

    Society and culture

Economics

The UK NHS in 2019 listed Humira, Amgevita, Hulio, Hyrimoz, Idacio, and Imraldi as biosimilars available on prescription, to be updated in February 2022. The annual cost of adalimumab, the costliest NHS drug, was expected to drop from £400m to £100m by 2021, the biggest saving in NHS history from a single drug negotiation.
The best-selling drugs list published by Genetic Engineering & Biotechnology News, shows that Humira occupied the position for 2015 and 2016 From 2012 until the US patent expired in 2016, Humira led the list of top-selling pharmaceutical products, and in 2016, it had of global sales. AbbVie reported that Humira achieved of sales in 2017. Humira had the largest worldwide drug sales in 2019 and 2020 of US$19.7bn and US$20.4bn respectively.